2 research outputs found
Epidemiology and aetiology of dialysis-treated end-stage kidney disease in Libya
Abstract Background The extent and the distribution of end stage kidney disease (ESKD) in Libya have not been reported despite provision of dialysis over 4 decades. This study aimed to develop the first comprehensive description of the epidemiology of dialysis-treated ESKD in Libya. Methods Structured demographic and clinical data were obtained regarding all adult patients treated at all maintenance dialysis facilities (n=39) in Libya from May to September 2009. Subsequently data were collected prospectively on all new patients who started dialysis from September 2009 to August 2010. Population estimates were obtained from the Libyan national statistics department. The age and gender breakdown of the population in each region was obtained from mid-2009 population estimates based on 2006 census data. Results The prevalence of dialysis-treated ESKD was 624 per million population (pmp). 85% of prevalent patients were aged Conclusions Libya has a relatively high prevalence and incidence of dialysis-treated ESKD. As the country prepares to redevelop its healthcare system it is hoped that these data will guide strategies for the prevention of CKD and planning for the provision of renal replacement therapy.</p
Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors
Background: Patients receiving maintenance haemodialysis (HD) are at higher risk for acquiring Hepatitis B Virus
(HBV) and Hepatitis C Virus (HCV) infections than the general population. Strict infection control measures are
essential to prevent nosocomial transmission. We aimed to investigate the incidence and prevalence of HBV and
HCV infection in the HD population of Libya as well as risk factors for infection.
Methods: All adult patients receiving maintenance HD (n=2382) in Libyan dialysis centres (n=39) were studied
between May 2009 and October 2010. Testing for Hepatitis B surface antigen (HBsAg) and anti-HCV antibodies was
performed at initiation of dialysis and every 3–6 months thereafter. Patients who were sero-negative for HBV and
HCV (n=1160) were followed up for 1 year to detect sero-conversions.
Results: Participant median age was 49 years and 58% were male. 831 patients (34.9%) were sero-positive for HBV
and/or HCV (anti-HCV positive 31.1%; HBsAg positive 2.6%; both positive 1.2%). Of the sero-positive patients
4.7% were known to be infected before the initiation of HD. The prevalence of HBV±HCV infection varied widely
between HD centres from 0% to 75.9%. Sero-positive patients were younger, had longer time on dialysis and more
previous blood transfusions. Prospective follow-up revealed an incidence of sero-conversion of 7.7% during 1 year
(7.1% HCV; 0.6% HBV). Wide variation in rates of newly acquired infections was observed between dialysis centres.
All new HBV cases were referred from centres already treating HBV infected patients. New HCV infections were
reported in most centres but the rate of HCV sero-conversion varied widely from 1.5% to 31%. Duration of dialysis,
history of previous renal transplant and history of receiving HD in another centre in Libya were significantly
associated with sero-conversion.
Conclusion: Patients on maintenance HD in Libya have a high incidence and prevalence of HCV infection and
lower rates of HBV infection. The factors associated with HBV and HCV infection are highly suggestive of
nosocomial transmission within HD units. Urgent action is required to improve infection control measures in HD
centres and to reduce dependence on blood transfusions for the treatment of anaemia.
Keywords: Haemodialysis, Hepatitis B, Hepatitis C, Incidence, Libya, Nosocomial infection, Prevalenc